Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Repligen's profit margin for the twelve months ending Sep 30, 2026 was -1.5%. For fiscal 2025 it was 6.6%, against -4.0% the year before. The highest annual figure on record is 23.6% in fiscal 2013.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.6% | +10.6 |
| FY2024 | Dec 31, 2024 | -4.0% | −9.7 |
| FY2023 | Dec 31, 2023 | 5.6% | −17.6 |
| FY2022 | Dec 31, 2022 | 23.2% | +4.1 |
| FY2021 | Dec 31, 2021 | 19.1% | +2.8 |
| FY2020 | Dec 31, 2020 | 16.4% | +8.4 |
| FY2019 | Dec 31, 2019 | 7.9% | −0.6 |
| FY2018 | Dec 31, 2018 | 8.6% | −11.5 |
| FY2017 | Dec 31, 2017 | 20.1% | +8.9 |
| FY2016 | Dec 31, 2016 | 11.2% | −0.0 |
| FY2015 | Dec 31, 2015 | 11.2% | −1.7 |
| FY2014 | Dec 31, 2014 | 12.9% | −10.8 |
| FY2013 | Dec 31, 2013 | 23.6% | +23.8 |
| FY2011 | Mar 31, 2011 | -0.2% | +19.2 |
| FY2010 | Mar 31, 2010 | -19.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -18.4% | −26.3 |
| Q2 FY2026 | Jun 30, 2026 | 2.5% | −5.7 |
| Q1 FY2026 | Mar 31, 2026 | 4.3% | +0.8 |
| Q4 FY2025 | Dec 31, 2025 | 6.7% | +26.9 |
| Q3 FY2025 | Sep 30, 2025 | 7.9% | +8.3 |
| Q2 FY2025 | Jun 30, 2025 | 8.2% | +4.6 |
| Q1 FY2025 | Mar 31, 2025 | 3.4% | +1.3 |
| Q4 FY2024 | Dec 31, 2024 | -20.2% | −10.3 |
| Q3 FY2024 | Sep 30, 2024 | -0.4% | −12.4 |
| Q2 FY2024 | Jun 30, 2024 | 3.6% | −8.8 |
| Q1 FY2024 | Mar 31, 2024 | 2.2% | −7.1 |
| Q4 FY2023 | Dec 31, 2023 | -9.9% | −36.0 |
| Q3 FY2023 | Sep 30, 2023 | 12.0% | −8.1 |
| Q2 FY2023 | Jun 30, 2023 | 12.4% | −11.6 |
| Q1 FY2023 | Mar 31, 2023 | 9.3% | −13.5 |
| Q4 FY2022 | Dec 31, 2022 | 26.1% | +10.5 |
| Q3 FY2022 | Sep 30, 2022 | 20.1% | +1.3 |
| Q2 FY2022 | Jun 30, 2022 | 24.0% | +1.8 |
| Q1 FY2022 | Mar 31, 2022 | 22.8% | +2.1 |
| Q4 FY2021 | Dec 31, 2021 | 15.6% | −2.5 |
| Q3 FY2021 | Sep 30, 2021 | 18.8% | +3.3 |
| Q2 FY2021 | Jun 30, 2021 | 22.2% | +4.1 |
| Q1 FY2021 | Mar 31, 2021 | 20.6% | +7.7 |
| Q4 FY2020 | Dec 31, 2020 | 18.1% | +12.9 |
| Q3 FY2020 | Sep 30, 2020 | 15.5% | +13.1 |
| Q2 FY2020 | Jun 30, 2020 | 18.1% | +6.7 |
| Q1 FY2020 | Mar 31, 2020 | 12.9% | −0.4 |
| Q4 FY2019 | Dec 31, 2019 | 5.2% | −5.7 |
| Q3 FY2019 | Sep 30, 2019 | 2.4% | −7.3 |
| Q2 FY2019 | Jun 30, 2019 | 11.5% | +5.7 |
| Q1 FY2019 | Mar 31, 2019 | 13.3% | +5.6 |
| Q4 FY2018 | Dec 31, 2018 | 10.9% | −18.4 |
| Q3 FY2018 | Sep 30, 2018 | 9.7% | −3.1 |
| Q2 FY2018 | Jun 30, 2018 | 5.7% | −20.3 |
| Q1 FY2018 | Mar 31, 2018 | 7.7% | −2.3 |
| Q4 FY2017 | Dec 31, 2017 | 29.3% | +9.6 |
| Q3 FY2017 | Sep 30, 2017 | 12.8% | – |
| Q2 FY2017 | Jun 30, 2017 | 26.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 10.0% | – |
| Q4 FY2016 | Dec 31, 2016 | 19.6% | – |
See a number that looks wrong?